Krishna Koradia D, Pradip Sidhdhapara T, Navin Sheth R
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot 360005, Gujarat. India.
Recent Pat Drug Deliv Formul. 2017;11(2):124-131. doi: 10.2174/1872211311666170213105001.
Naratriptan is second-generation triptan class of antimigraine drug which selectively bind with 5-HT(1B/1D) receptor. It is widely used to treat the migraine attack due to its better tolerability and lower recurrence rate as compared to other triptans. Despite of the applicability, Naratriptan also have several drawback like slow onset of action and fist pass metabolism which reduce its efficacy. In order to increase the efficacy of naratriptan fast dissolving film is prepared.
Fast dissolving film of Naratriptan hydrochloride was prepared by solvent casting method Based on the patent survey (US 7648712 B2, WO 2012053006 A2, US 20090047330 A1, EP 2821066 A4, WO 2008108940 A1, WO 2010151020 A3) excipients were screened to find out suitable combination of polymer and plasticizer and Hydroxypropylmethyl Cellulose (HPMC E6) and glycerol were selected as film forming polymer and plasticizer respectively. To study the effect of independent variables on dependent variables 32 full factorial design was applied using Concentration of HPMC E6 and Concentration of Glycerol as independent variables and disintegration time, folding endurance, tensile strength and cumulative % drug release at 2 min as dependent or response variables. A statistical model incorporating interactive and polynomial terms was utilized to evaluate the responses. Result & Conclusion: From the results of statistical evaluation batch F3 was selected as the optimized batch which exhibited shorter disintegration time (22sec) with satisfactory mechanical properties (tensile strength 652.17 gm/mm2). Dissolution of drug from F3 formulation was rapid with around 91% drug release in 120sec. Optimized batch was further evaluated for in vitro permeation study using Franz diffusion cell.
那拉曲普坦是第二代曲坦类抗偏头痛药物,可选择性地与5-HT(1B/1D)受体结合。与其他曲坦类药物相比,它具有更好的耐受性和更低的复发率,因此被广泛用于治疗偏头痛发作。尽管具有适用性,但那拉曲普坦也有一些缺点,如起效缓慢和首过代谢,这降低了它的疗效。为了提高那拉曲普坦的疗效,制备了速溶膜。
采用溶剂浇铸法制备盐酸那拉曲普坦速溶膜。基于专利调研(美国专利7648712 B2、WO 2012053006 A2、美国专利20090047330 A1、欧洲专利2821066 A4、WO 2008108940 A1、WO 2010151020 A3)筛选辅料,以找出聚合物和增塑剂的合适组合,分别选择羟丙基甲基纤维素(HPMC E6)和甘油作为成膜聚合物和增塑剂。为了研究自变量对因变量的影响,以HPMC E6浓度和甘油浓度作为自变量,崩解时间、耐折性、拉伸强度和2分钟时的药物累积释放率作为因变量或响应变量,应用32全因子设计。利用包含交互项和多项式项的统计模型来评估响应。结果与结论:根据统计评估结果,选择批次F3作为优化批次,其崩解时间较短(22秒),机械性能良好(拉伸强度652.17克/毫米2)。F3制剂中药物的溶出迅速,120秒内药物释放约91%。使用Franz扩散池对优化批次进行体外渗透研究的进一步评估。